Neisseria gonorrhoeae strains resistant to treatment with penicillin, tetracycline, and/or spectinomycin are increasing in prevalence in many parts of the world. In Zambia, 52% of N. gonorrhoeae isolates produced ,-lactamase in 1986. Few oral regimens have proven effective for treatment of resistant N. gonorrhoeae. We conducted a prospective, double-blind, randomized clinical trial of 250 mg of ciprofloxacin given orally versus 250 mg of ceftriaxone given intramuscularly for treatment of uncomplicated gonococcal urethritis in adult males. Two hundred men were enrolled and treated. The two groups were comparable in age (27.5 years), prevalence of latent syphilis (14 and 10%), and human immunodeficiency virus infection (32 and 38%). Of 165 patients with cultures positive for N. gonorrhoeae who returned for follow-up, ciprofloxacin cured 83 of 83 (100%), including 26 with penicillinase-producing N. gonorrhoeae (PPNG) and 21 with N. gonorrhoeae with chromosomally mediated resistance to multiple antibiotics (CMRNG), and ceftriaxone cured 81 of 82 (98.7%), including 30 with PPNG and 19 with CMRNG. Both treatment regimens were well tolerated. Chiamydia trachomatis in urethral exudate was found by direct fluorescent-antibody microscopic examination or by culture in 10 (5%) participants. All N. gonorrhoeae isolates were inhibited by ceftriaxone at 0.06 ,ug/ml, except one which was inhibited at 0.125 ,ug/ml, while ciprofloxacin inhibited all isolates at 0.03 ,ug/ml. Ciprofloxacin is a safe and effective therapy for uncomplicated gonococcal urethritis, including that caused by PPNG and CMRNG in human immunodeficiency virus-infected men.
Although the incidence of gonorrhea in the United States has been decreasing over the past 10 years, this trend may be reversing among some groups (7) . During this time, the treatment of gonorrhea has been complicated by the emergence of strains resistant to penicillin, tetracycline, and spectinomycin (10, 17, 18, 29 ; J. S. Moran and J. M. Zenilman, Rev. Infect. Dis., in press). The number of reported cases of penicillinase-producing N. gonorrhoeae (PPNG) in the United States increased almost eightfold between 1984 and 1988 to 33,491 cases annually (24; Statistics Branch, Division of Sexually Transmitted Diseases, Centers for Disease Control, Atlanta, Ga.). In Zambia, gonorrhea was the most commonly diagnosed sexually transmitted disease in 1986 with 26,744 cases reported annually, compared with 13,772 cases of chancroid (Health Statistics, Government of Zambia). The percentage of isolates producing ,-lactamase at the Dermato-Venereology Clinic at the University Teaching Hospital in Lusaka increased from 3.2% in 1980 to 52% in 1986 (11; our unpublished data), necessitating the use of kanamycin, gentamicin, or spectinomycin as the parenteral therapy of choice for gonococcal urethritis.
Ciprofloxacin, a new fluorinated carboxyquinolone, achieves high concentrations in urethral and prostatic secretions and is very active in vitro against N. gonorrhoeae (23, 28) . It is effective as single-dose oral therapy for gonococcal urethritis (1, 2, 23) , but only limited experience has been acquired with penicillinase-producing strains (PPNG) intramuscularly plus a placebo capsule by mouth, identical in appearance to ciprofloxacin capsules. Because ceftriaxone is yellow in solution, unlike saline, the double-blind nature of the trial was maintained by sheathing the syringe. Patients were observed for 30 min in the clinic. They were requested to abstain from sexual contact until after the second follow-up visit at 10 days. At the follow-up visits, 3 to 5 and 7 to 10 days after therapy, urethral cultures for N. gonorrhoeae were taken and patients were questioned about side effects of the medication. Repeat specimens for chlamydiae were not taken. At the second follow-up, those with serology reactive for syphilis were treated with benzathine penicillin in appropriate doses and follow-up visits for repeat serology tests were scheduled. Patients with Chlamydia infection, as determined by direct fluorescent-antibody examination, were treated with tetracycline (500 mg) four times daily for 7 days. Follow-up for all sexual partners was recommended. Those with antibody to HIV were referred to trained counselors within the dermato-venereology clinic for management.
Isolation of N. gonorrhoeae and Chiamydia trachomatis. Urethral, rectal, and pharyngeal specimens for N. gonorrhoeae as well as urethral swabs for Chlamydia culture and direct fluorescent-antibody examination of urethral smears (MicroTrak, Syva Corp., Palo Alto, Calif.) were obtained from all patients. N. gonorrhoeae strains were isolated and identified by standard techniques. Production of P-lactamase was determined by a ceph-lactam disk (Remel, Lenexa, Kans.). A heavy inoculum of an 18-h subculture of each isolate was placed in a mixture of glycerol and Trypticase soy broth (BBL Microbiology Systems, Cockeysville, Md.) in a ratio of 1:1 and placed at -70°C or in liquid nitrogen. Urethral swabs for C. trachomatis were placed into 0.2 M sucrose-phosphate-buffered solution and stored at -70°C for culture in the United States. Gonococci and chlamydiae were transported under dry ice. Chlamydia cultures were done under contract with the University of Washington.
Antimicrobial susceptibility testing. Isolates were tested in the sexually transmitted disease research lab at Johns Hopkins University, Baltimore, Md. The MICs of ceftriaxone, ciprofloxacin, penicillin, tetracycline, spectinomycin, and kanamycin were determined by the agar dilution method by using standard techniques (16) . Isolates without plasmidmediated resistance were defined as resistant by chromosomal mediation (CMRNG) if the MIC of penicillin and tetracycline was .2.0 (10) . Isolates were determined to be resistant to spectinomycin if the MIC was .128 ,ug/ml and resistant to kanamycin if the MIC was .32 ,ug/ml (16 
RESULTS
Study population. Two hundred men were enrolled and treated. The ciprofloxacin and ceftriaxone groups were comparable in age (27.5 years), prevalence of latent syphilis (14% and 10%), HIV infection (32 and 38%), number with chlamydiae (determined by smear or culture) (5%), number returning for follow-up (85 in each group), number with cultures negative for N. gonorrhoeae (2 and 3), and number infected with PPNG or CMRNG. Approximately one-third of the subjects were infected with HIV. No patient had neutropenia or lymphopenia, and none had clinical evidence of immunosuppression. Characteristics of patients who were evaluable on days 3 to 5 are given in Table 1 .
Clinical and microbiologic results. No patient had a culture positive for N. gonorrhoeae from the rectum or pharynx. Of the 165 patients who returned for follow-up evaluation and who had a positive pretreatment culture for N. gonorrhoeae, only one patient (in the ceftriaxone group) had a positive posttreatment urethral culture ( Table 1 ). The patient admitted sexual reexposure to an untreated partner. All 112 patients who returned for follow-up at 7 to 10 days remained free of infection. Only one patient reported post-gonococcal urethritis symptoms, i.e., slight dysuria. Pretreatment urethral specimens showed C. trachomatis. The other seven patients infected with C. trachomatis did not complain of urethritis symptoms on follow-up.
Toxicity and tolerance. Both ciprofloxacin and ceftriaxone were well tolerated by all patients. None complained of gastrointestinal or central nervous system symptoms, and no allergic reactions were observed or reported. Mild discomfort at the site of injection was noted in those receiving either intramuscular ceftriaxone or placebo.
Antimicrobial susceptibility of N. gonorrhoeae. Susceptibility data for ciprofloxacin and ceftriaxone were as follows. The MICs for 50 and 90% of isolates tested were 0.004 and 0.008 ,ug/ml, respectively, for both drugs. MIC ranges were '0.001 to 0.03 ,ug/ml for ciprofloxacin and '0.001 to 0.125 ,ug/ml for ceftriaxone. Of 195 pretreatment isolates tested, 65 produced P-lactamase. Additional The prevalence of C. trachomatis (5%) in this study was similar to that in other central African countries (20) and much lower than the 14 to 36% seen in contemporary heterosexual men with gonorrhea in the United States (3).
While ciprofloxacin has in vitro activity against C. trachomatis, a single dose has not been effective in eradicating C.
trachomatis from either the urethra or the rectum (1, 2, 23 ).
In addition, the quinolones ofloxacin and ciprofloxacin have not been effective in treating syphilitic orchitis in the rabbit model (22, 27 1061, 1989) . Spread of these strains to other areas appears to be occurring (14) .
Oral therapy for gonorrhea offers several advantages. These include ease of administration, patient acceptance, decreased cost, and fewer side effects compared with injections. Newer oral quinolones differ in pharmacokinetics and in vitro activity (6, 18, 21, 28) . However, in view of the proven efficacy of single-dose therapy with newer quinolones for urethral gonorrhea (9, 22) and lack of single-dose efficacy against chlamydiae without significant adverse effects (13, 25) , the main factors in choosing which quinolone to use are cost and adverse effects (13 
